Fears and hopes of patients with rheumatic and musculoskeletal diseases during the COVID‐19 pandemic across Europe. Results from the REUMAVID study (phase 1 and phase 2)
Musculoskeletal Care · 2023
DOI: 10.1002/msc.1750 ↗At a glance
Journal article in Musculoskeletal Care, 2023. Written by Marco Garrido-Cumbrera and 5 co-authors. Institution: Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain. Major MEDLINE topics: COVID-19, Musculoskeletal Diseases, Rheumatic Diseases. 11 references. The full text is freely available (open access, CC BY-NC-ND 4.0).
Abstract (original language)
Patients with rheumatic and musculoskeletal diseases (RMDs) lived through the first wave of the COVID-19 pandemic in Europe with a great degree of uncertainty, constant changes in the confinement measures and overwhelming media coverage causing severe distress (Dong & Zheng, 2020). Many saw their regular disease management interrupted, with limited access to their clinical care team (Garrido-Cumbrera et al., 2021). Early research suggested that some drugs commonly used in the treatment of RMDs were associated with more severe COVID-19 disease or mortality while others may have had protective effects (Putman et al., 2021). Such conflicting information together with the fear of contracting the COVID-19 virus infection, may have contributed to RMD patients adhering more strictly to the confinement measures as compared to the general population (Hooijberg et al., 2020). Furthermore, patients had to cope on their own with the most important public health challenge of modern society, facing queries that even trusted health institutions such as the World Health Organization (WHO) or the scientific community were not yet prepared to answer, including “Am I at greater risk of contracting COVID-19 because of my rheumatic disease?” or “If I get COVID-19, will I be more vulnerable due to my immunosuppressant medication” (Landewé et al., 2020). Given these circumstances, it became imperative to understand the true journey of RMD patients through the pandemic, as reported from their own perspective, in order to accurately identify unmet needs and inform meaningful response measures. Therefore, the present study aimed to assess COVID-19-related fears and hopes in patients with RMDs during the first stages of the pandemic in Europe. REUMAVID is a multidisciplinary international consortium assembled at the start of the COVID-19 pandemic aiming to explore its impact on RMD patients from seven European countries (Cyprus, France, Greece, Italy, Portugal, Spain, and the UK). Data were collected across two phases; phase 1 (April–July 2020) and phase 2 (February–April 2021) with recruitment conducted by patient organizations. REUMAVID was first approved by the ethical committee of University Hospital La Paz, Spain, under the code PI-4121 and was subsequently approved in all other participating countries as legally required. The seminal article describing the study is published elsewhere (Garrido-Cumbrera et al., 2021). Understanding patients' emotional response to the pandemic, including their actual fears and hopes was an important objective of REUMAVID. Together, the patient research partners and study psychologists developed a set of fears and hopes (Table 1). Participants were asked to rate these fears and hopes on a scale from zero (“no concern/hopeful at all”) to five (“extremely concerned/hopeful”). Mann-Whitney test were used to analyse the differences between fears and hopes in both REUMAVID phases. A total of 1800 and 2002 patients participated during the first (2020) and second (2021) phases of REUMAVID. Compared to the first phase in 2020, patients in 2021 had a mean age of 55.0 years (vs. 52.6 years in 2020), 83.7% were female (vs. 80.2% in 2020), 68.3% were married (vs. 69.6% in 2020) and 47.8% had university education (vs. 48.6% in 2020). In 2020 the most frequently represented RMD was axial spondyloarthritis (37.2%), while in 2021 it was rheumatoid arthritis (53.1%). During the first stage of the pandemic in 2020 patients were more afraid of the potential lack of access to medications and availability of these in their own country (p < 0.001), increased fears of possible popular uprising (p = 0.001) and risk of job loss (p = 0.003). However, patient's fears during 2021 were around their risk of infection associated to their illness (p = 0.04; Table 2). Compared to 2020, patients in 2021 were more hopeful of the prospect of successful vaccination against COVID-19 (p < 0.001); of going out (p < 0.001) and travelling as before the COVID-19 pandemic (p < 0.001); of maintaining and even improving their current economic situation after the COVID-19 pandemic (p < 0.001) and of continuing their treatment as usual (p = 0.049; Table 3). These data comprising the early phases of the COVID-19 pandemic show that the greatest fear for people affected by RMDs was the significant impact that the pandemic could have in their future healthcare. While in 2020 the greatest hope was to be able to continue treatment, in 2021 it was the availability of a COVID-19 treatment or vaccine. Reassuringly, whilst patients were more fearful in 2020, they appeared to be more hopeful during 2021. Fear is a powerful emotion with a strong impact in mind and body that can occur in any situation of stress, especially in people with chronic diseases (Tzur Bitan et al., 2020). The mass fear of COVID-19, characterized by its novelty, uncertainty and magnitude, has been termed as “coronaphobia.” A recent qualitative study highlighted how the main fears of the general population were the risk of infection and impact on healthcare, in that order (Mertens et al., 2020). In our study, however, RMD patients feared healthcare impact over the risk of contracting the infection. RMDs are chronic diseases and patients depend on their long term treatments in order to maintain their normal social and physical functioning (Garrido-Cumbrera et al., 2020), thus, it is understandable that as the pandemic negatively affected their routine management, their fear would consequently increase. Nevertheless, RMD patients' fear of increased risk of infection due to their immunosuppressant medication is of relevance. To understand it, it is important to remember that during 2020 of the pandemic, research on the effects of anti-rheumatic treatments on COVID-19 outcomes was sometimes contradictory, and limited to observational studies with low sample size (Ladani et al., 2020). Lack of information turned into misinformation when patients encountered barriers contacting their healthcare professionals, which led to patients seeking answers in other sources which were at times sub-optimal (Reuter et al., 2021). This so called “infodemic” led the WHO to issue a series of considerations to be taken into account in communications relating to the COVID-19 pandemic also recommending minimizing news and promoting only information from trusted sources (World Health Organization, 2020). Among the latter, patient organizations fulfilled a critical role, being ideally placed and having the potential to obtain and provide credible information to patients quickly and effectively. Overall, the COVID-19 pandemic has created significant uncertainty for RMD patients, as reflected in their fears. Yet despite their concerns, patients with RMDs remained hopeful. Providing patients clear information targeted at addressing their fears and hopes is critical for ensuring optimal self-management, treatment adherence, mental health, and quality of life. Furthermore, implementing an evidence-based response to COVID-19 and future crisis based on real patient needs is critical for ensuring their prompt adoption and long-term success. The possible impact of the COVID-19 pandemic on future healthcare was the major fear or concern for people affected by chronic RMDs across Europe during 2020 and 2021. The greatest hope in 2020 was to be able to continue with their treatment as usual while in 2021 it was the availability of a successful treatment or vaccine against COVID-19. Based on our results, people with RMDs were more fearful during the first phase of pandemic in 2020 but became more hopeful in 2021. Providing patients with clear information targeted at addressing their fears is critical for ensuring optimal self-management and reducing stress during the ongoing COVID-19 pandemic. The authors confirm contribution to the paper as follows: study conception and design: Marco Garrido-Cumbrera, José Correa-Fernández, Helena Marzo-Ortega, Sergio Sanz-Gomez, Victoria Navarro-Compán, Laura Christen; data collection: Marco Garrido-Cumbrera, José Correa-Fernández; analysis and interpretation of results: José Correa-Fernández, Marco Garrido-Cumbrera, Sergio Sanz-Gomez, Victoria Navarro-Compán, Laura Christen, Helena Marzo-Ortega; draft manuscript preparation: Marco Garrido-Cumbrera, José Correa-Fernández, Sergio Sanz-Gomez, Victoria Navarro-Compán, Helena Marzo-Ortega, Laura Christen. All authors reviewed the results and approved the final version of the manuscript. We would like to thank all of the patients who completed the survey, as well as all of the patient organisations and patient representatives who participated in the REUMAVID study including: Souzi Makri from the Cyprus League for People with Rheumatism (CYLPER) from Cyprus, the Association Française de Lutte Anti-Rhumatismale (AFLAR) from France, Katy Antonopoulou from the Hellenic League Against Rheumatism (ELEANA) from Greece, the Associazione Nazionale Persone con Malattie Reumatologiche e Rare (APMAAR) from Italy, Elsa Frazão Mateus from the Portuguese League Against Rheumatic Diseases (LCPDR) from Portugal, Pedro Plazuelo-Ramos from the Spanish Federation of Spondyloarthritis Associations (CEADE), the Spanish Patients' Forum, UNiMiD, Spanish Rheumatology League (LIRE), Andalusian Rheumatology League (LIRA), Catalonia Rheumatology League and Galician Rheumatology League from Spain, and Jim Hamilton from the National Axial Spondyloarthritis Society (NASS), Clare Jacklin and Ailsa Bosworth from the National Rheumatoid Arthritis (NRAS), Shantel Irwin from Arthritis Action from the UK. We would further like to thank Patricia Pertel, Maria-Magdalena Balp, and Marina Milutinovic of Novartis Pharma AG for their contributions to the study design and execution. H Marzo-Ortega is supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre (LBRC). The REUMAVID study is supported by Novartis Pharma AG. MG-C reports grant/research support from: Novartis. HM-O reports grant/research support from: Janssen and Novartis, consultant for: AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB, speakers’ bureau: AbbVie, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Takeda and UCB. HM-O is supported by the National Institute for Health Research (NIHR) Leeds Biomedical Research Centre. LC is an employee of Novartis Pharma AG. VN-C reports honoraria/research support from: Abbvie, BMS, Janssen, Lilly, MSD, Novartis, Pfizer, Roche and UCB. REUMAVID was first approved by the ethical committee of University Hospital La Paz under the code PI-4121 and was subsequently approved in all other participating countries as legally required. The data that support the findings of this study are available from the corresponding author upon reasonable request.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- Health & Territory Research (HTR), Universidad de Sevilla, Seville, Spain.
- Spanish Federation of Spondyloarthritis Associations (CEADE), Madrid, Spain.
- Axial Spondyloarthritis International Federation (ASIF), London, UK.
- Novartis Pharma AG, Basel, Switzerland.
- NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK.
- Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
ORCID profiles: Marco Garrido-Cumbrera
Cite
APA
Garrido-Cumbrera, M., Christen, L., Marzo-Ortega, H., Correa-Fernández, J., Sanz-Gomez, S., & Navarro-Compán, V. (2023). Fears and hopes of patients with rheumatic and musculoskeletal diseases during the COVID‐19 pandemic across Europe. Results from the REUMAVID study (phase 1 and phase 2). Musculoskeletal Care. https://doi.org/10.1002/msc.1750
Vancouver
Garrido-Cumbrera M, Christen L, Marzo-Ortega H, Correa-Fernández J, Sanz-Gomez S, Navarro-Compán V. Fears and hopes of patients with rheumatic and musculoskeletal diseases during the COVID‐19 pandemic across Europe. Results from the REUMAVID study (phase 1 and phase 2). Musculoskeletal Care. 2023. doi:10.1002/msc.1750
BibTeX
@article{GarridoCumbrera2023,
author = {Garrido-Cumbrera, Marco and Christen, Laura and Marzo-Ortega, Helena and Correa-Fernández, José and Sanz-Gomez, Sergio and Navarro-Compán, Victoria},
title = {Fears and hopes of patients with rheumatic and musculoskeletal diseases during the COVID‐19 pandemic across Europe. Results from the REUMAVID study (phase 1 and phase 2)},
journal = {Musculoskeletal Care},
year = {2023},
doi = {10.1002/msc.1750}
}
EUVIMED